Molecular Genetics of Endometrial Cancers

Gynecologic Cancer: Controversies in Management

Volumn , Issue , 2004, Pages 229-239

  Goodfellow, Paul J ^a   Mutch, David G ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47249105282     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-07142-3.50020-8     Document Type: Chapter

References (111)

1. TS Frank and GC Critchfield (2002) Inherited risk of women's cancers: What's changed for the practicing physician? Clin Obstet Gynecol 45 671-683.
2. M Aarnio, R Sankila, E Pukkala, et al. (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81 214-218.
3. HFA Vasen, JT Wijnen, FH Menko, et al. (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 1020-1027.
4. CL Kosary, LAG Ries, BA Miller, et al. (1995) SEER Cancer Statistics Review, 1973-1992. NIH no. 96-2789 Bethesda, MD: National Institutes of Health
5. SR Brown, PJ Finan and DT Bishop (1998) Are relatives of patients with multiple HNPCC spectrum tumours at increased risk of cancer? Gut 43 664-668.
6. T Pal, T Flanders, M Mitchell-Lehman, et al. (1998) Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet 35 978-984.
7. AL Millar, T Pal, L Madlensky, et al. (1999) Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 9 823-829.
8. Buttin BM, Powell MA, Mutch DG, et al: Increased risk for HNPCC-associated synchronous and metachronous malignancies in patients with MSI-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res (submitted).
9. HT Lynch and A de la Chapelle (2003) Hereditary colorectal cancer. N Engl J Med 348 919-932.
10. PJ Goodfellow, BM Buttin, TJ Herzog, et al. (2003) Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 100 5908-5913.
11. M Esteller, R Levine, SB Baylin, et al. (1998) MLH1 promoter hyper-methylation is associated with the microsatellite instability pheno-type in sporadic endometrial carcinomas. Oncogene 16 2413-2417.
12. SB Simpkins, A Whelan, S Babb, et al. (1999) Hypomethylation of the MLH1 promoter region in MSI-positive endometrial carcinomas may be an indicator of inherited cancer susceptibility. Proceed Am Assoc Cancer Res 40 141-142.
13. CC Gurin, MG Federici, L Kang and J Boyd (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Can Res 59 462-466.
14. Berchuck A, Mutch DG, Karlan BY: The how, when and why of surgical prophylaxis in the high risk patient: Hereditary ovarian and endometrial cancers. J Clin Onc (in press).
15. W Burke, G Petersen, P Lynch, et al. (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277 915-919.
16. P Watson and HT Lynch (1994) The tumor spectrum in HNPCC. Anticancer Res 14 1635-1640.
17. HF Vasen, JP Mecklin, PM Khan and HT Lynch (1994) The International Collaborative Group on HNPCC. Anticancer Res 14 1661-1664.
18. M Aarnio, JP Mecklin, LA Aaltonen, et al. (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64 430-433.
19. HFA Vasen, A Stormorken, FH Menko, et al. (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19 4074-4080.
20. I Dove-Edwin, D Boks, S Goff, et al. (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94 1708-1712.
21. DE Boks, AP Trujillo, AC Voogd, et al. (2002) Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 102 198-200.
22. ER Fearon and B Vogelstein (1990) A genetic model for colorectal tumorigenesis. Cell 61 759-767.
23. KW Kinzler and B Vogelstein (1996) Lessons from hereditary colorectal cancer. Cell 87 159-170.
24. LA Loeb (2001) A mutator phenotype in cancer. Cancer Res 61 3230-3239.
25. CM Ribic, DJ Sargent, MJ Moore, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 247-257.
26. D Coradini, S Oriana, E Biganzoli, et al. (1999) Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer. Int J Biol Markers 14 60-67.
27. JM Harvey, GM Clark, K Osborne and DC Allred (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 1474-1481.
28. FC Campbell, RW Blamey, CW Elston, et al. (1981) Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2 1317-1319.
29. R Valavaara, J Tuominen and R Johansson (1990) Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with tamoxifen. Cancer 66 2264-2269.
30. DJ Slamon, B Leyland-Jones, S Shak, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 783-792.
31. B Jereczek-Fossa, A Badzio and J Jassem (1999) Surgery followed by radiotherapy in endometrial cancer: Analysis of survival and patterns of failure. Int J Gynecol Cancer 9 285-294.
32. CL Creutzberg, WL van Putten, PC Koper, et al. (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC study group: Postoperative radiation therapy in endometrial carcinoma. Lancet 355 1404-1411.
33. J Roberts, V Brunetto, H Keys, et al. (1998) A phase III randomized study of surgery vs. surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma [abstract]. Presented at the 29th Annual Meeting of the Society of Gynecologic Oncologists. February 35 70.
34. C MacLeod, AR Fowler, I Ogino, et al. (1999) High-dose-rate brachytherapy in the management of cervical and vaginal intraepithelial neoplasia Int J Radiat Oncol Biol Phys 1998;40:881-887. Int J Radiat Oncol Biol Phys 43 235-236.
35. BW Corn, RM Lanciano, KM Greven, et al. (1994) Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: A multivariate analysis. J Clin Oncol 12 510-515.
36. G Lewandowski, J Torrisi, RK Potkul, et al. (1990) Hysterectomy with extended surgical staging and radiotherapy versus hysterectomy alone and radiotherapy in stage I endometrial cancer: A comparison of complication rates. Gynecol Oncol 36 401-404.
37. L Hedrick (1998) The genetic basis of human cancer. B Vogelstein, KW Kinzler (Eds) Endometrial Cancer New York: McGraw-Hill 621-629.
38. Goodfellow P: Molecular genetics of uterine malignancies. In Rubin SC, Coukos G (eds): Cancer of the Uterus. New York, Marcel Dekker (in press).
39. JV Bokhman (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 10-17.
40. L Deligdisch and CF Holinka (1987) Endometrial carcinoma: Two diseases? Cancer Detect Prevent 10 237-246.
41. RJ Kurman and HJ Norris (1987) Blaustein's Pathology of the Female Genital Tract. RJ Kurman (Eds) Endometrial Carcinoma 3 ed. New York: Springer-Verlag 338-372.
42. G Von Minckwitz, W Kuhn, M Kaufmann, et al. (1994) Prognostic importance of DNA-ploidy and S-phase fraction in endometrial cancer. Int J Gynecol Cancer 4 250-256.
43. RJ Zaino, AT Davis, BM Ohlsson-Wilhelm and VL Brunetto (1998) DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 17 312-319.
44. G Mangili, P De Marzi, R Vigano, et al. (2002) Identification of high risk patients with endometrial carcinoma. Prognostic assessment of endometrial cancer. Eur J Gynaecol Oncol 23 216-220.
45. A Koul, PO Bendahl, A Borg, et al. (2002) TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. Int J Gynecol Cancer 12 362-371.
46. B Nordstrom, P Strang, R Bergstrom, et al. (1996) A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma: Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 78 1942-1951.
47. L Mariani, L Conti, A Antenucci, et al. (2000) Predictive value of cell kinetics in endometrial carcinoma. Anticancer Res 20 3569-3574.
48. A Mariani, TJ Sebo, JA Katzmann, GL Keeney, et al. (2000) Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 182 1535-1544.
49. DE Koshland Jr (1993) Molecule of the year. Science 262 1953.
50. Hum Mutat 21 173-330.
51. SA Ahrendt, Y Hu, M Buta, et al. (2003) P53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. J Natl Cancer Inst 95 961-970.
52. DF Tan, Q Li, N Rammath, et al. (2003) Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer. Anticancer Res 23 1665-1672.
53. E Rahko, G Blanco, Y Soini, et al. (2003) A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 39 447-453.
54. T Okuda, J Otsuka, A Sekizawa, et al. (2003) P53 mutations and over-expression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 88 318-325.
55. AL Borresen-Dale (2003) TP53 and breast cancer. Hum Mutat 21 292-300.
56. M Schuijer and EM Berns (2003) TP53 and ovarian cancer. Hum Mutat 21 285-291.
57. B Iacopetta (2003) TP53 mutation in colorectal cancer. Hum Mutat 21 271-276.
58. H Tashiro, C Isacson, R Levine, et al. (1997) P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150 177-185.
59. T Kihana, K Hamada, Y Inoue, et al. (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 76 72-78.
60. MF Kohler, A Berchuck, AM Davidoff, et al. (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52 1622-1627.
61. T Honda, H Kato, T Imamura, et al. (1993) Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 53 963-967.
62. EM Swisher, S Peiffer-Schneider, DG Mutch, et al. (1999) Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 85 119-126.
63. SS Wachtel, G Wachtel, LP Shulman, et al. (1994) Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism. J Soc Gynecol Invest 1 234-237.
64. T Enomoto, M Fujita, M Inoue, et al. (1993) Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53 1883-1888.
65. AS Elhafey, JC Papadimitriou, MS El-Hakim, et al. (2001) Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium. Arch Pathol Lab Med 125 872-879.
66. MB Silverman, PC Roche, RM Kho, et al. (2000) Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 77 1-7.
67. C Lundgren, G Auer, B Frankendal, et al. (2002) Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 12 110-118.
68. T Enomoto, M Inoue, AO Perantoni, et al. (1991) K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 51 5308-5314.
69. BD Duggan, JC Felix, LI Muderspach, et al. (1994) Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res 54 1604-1607.
70. D Ignar-Trowbridge, JI Risinger, GA Dent, et al. (1992) Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol 167 227-232.
71. H Sasaki, H Nishii, H Takahashi, et al. (1993) Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53 1906-1910.
72. RF Caduff, CM Johnston and TS Frank (1995) Mutations of the Ki-ras oncogene carcinoma of the endometrium. Am J Pathol 146 182-188.
73. H Lagarda, L Catasus, R Arguelles, et al. (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193 193-199.
74. SF Lax, B Kendall, H Tashiro, et al. (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 88 814-824.
75. DE Cohn, DG Mutch, TJ Herzog, et al. (2001) Genotypic and pheno-typic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes Cancer 32 295-301.
76. CA Long, TJ O'Brien, MM Sanders, et al. (1988) Ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol 159 1512-1516.
77. G Scambia, L Catozzi, P Benedetti-Panici, et al. (1993) Expression of ras p21 oncoprotein in normal and neoplastic human endometrium. Gynecol Oncol 50 339-346.
78. H Tsuda, K Jiko, M Yajima, et al. (1995) Frequent occurrence of c-Ki-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 14 255-259.
79. K Ito, K Watanabe, S Nasim, et al. (1996) K-ras point mutations in endometrial carcinoma: Effect on outcome is dependent on age of patient. Gynecol Oncol 63 238-246.
80. A Semczuk, H Berbec, M Kostuch, et al. (1998) K-ras gene point mutations in human endometrial carcinomas: Correlation with clinicopathological features and patients' outcome. J Cancer Res Clin Oncol 124 695-700.
81. SV Cardoso, HM Barbosa, IM Candellori, et al. (2002) Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch 441 174-178.
82. MG Joseph, D Banerjee, W Kocha, et al. (2001) Metallothionein expression in patients with small cell carcinoma of the lung: Correlation with other molecular markers and clinical outcome. Cancer 92 836-842.
83. Y Saga, H Hashimoto, S Yachiku, et al. (2002) Immunohistochemical expression of metallothionein in human bladder cancer: Correlation with histopathological parameters and patient survival. J Urol 168 2227-2231.
84. NN Lynn, MC Howe, RJ Hale, et al. (2003) Overexpression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J Urol 169 721-723.
85. RR Bahnson, M Becich, MS Ernstoff, et al. (1994) Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 152(Pt 2), 2272-2275.
86. AM Janssen, W van Duijn, FJ Kubben, et al. (2002) Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 8 1889-1896.
87. D Ofner, H Maier, B Riedmann, et al. (1994) Immunohistochemical metallothionein expression in colorectal adenocarcinoma: Correlation with tumour stage and patient survival. Virchows Arch 425 491-497.
88. Y Hishikawa, T Koji, DK Dhar, et al. (1999) Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81 712-720.
89. K Kishi, Y Doki, H Miyata, et al. (2002) Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89 597-603.
90. TA Aloia, DH Harpole Jr, CE Reed, et al. (2001) Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72 859-866.
91. EE Ioachim, E Kitsiou, C Carassavoglou, et al. (2000) Immunohistochemical localization of metallothionein in endometrial lesions. J Pathol 191 269-273.
92. WG McCluggage, P Maxwell, PW Hamilton and B Jasani (1999) High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 34 51-55.
93. Telomeres, Telomerase, and The Cancer Cell [whole issue]. Cancer Lett 194 137-247.
94. Y Maida, S Kyo, T Kanaya, et al. (2002) Is the telomerase assay useful for screening of endometrial lesions? Int J Cancer 100 714-718.
95. G Bonatz, W Klapper, A Barthe, et al. (1998) Analysis of telomerase expression and proliferative activity in the different layers of cyclic endometrium. Biochem Biophys Res Commun 253 214-221.
96. Y Ebina, H Yamada, T Fujino, et al. (1999) Telomerase activity correlates with histopathological factors in uterine endometrial carcinoma. Int J Cancer 84 529-532.
97. G Bonatz, SO Frahm, W Klapper, et al. (2001) High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol 32 605-614.
98. Y Yokoyama, X Wan, A Shinohara, et al. (2001) Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells. Hum Cell 14 223-231.
99. H Katabuchi, B van Rees, AR Lambers, et al. (1995) Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 55 5556-5560.
100. LD Kowalski, DG Mutch, TJ Herzog, et al. (1997) Mutational analysis of MLH1 and MSH2 in 25 prospectively acquired RER + endometrial cancers. Genes Chromosomes Cancer 18 219-227.
101. K Kobayashi, M Matsushima, S Koi, et al. (1996) Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res 87 141-145.
102. SB Simpkins, T Bocker, EM Swisher, et al. (1999) MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 8 661-666.
103. H Tashiro, SF Lax, PB Gaudin, et al. (1997) Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 150 75-79.
104. RF Caduff, CM Johnston, SM Svoboda-Newman, et al. (1996) Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 148 1671-1678.
105. R Gryfe, H Kim, ETK Hsieh, et al. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 69-77.
106. RA Lothe, P Peltomäki, GI Meling, et al. (1993) Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53 5849-5852.
107. JR Lukish, K Muro, J DeNobile, et al. (1998) Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227 51-56.
108. CM Wright, OF Dent, M Barker, et al. (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87 1197-1202.
109. GL Maxwell, JI Risinger, AA Alvarez, et al. (2001) Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97 417-422.
110. JB Basil, PJ Goodfellow, JS Rader, et al. (2000) Clinical significance of microsatellite instability in endometrial cancer. Cancer 89 1758-1764.
111. G Peiro, J Diebold, P Lohse, et al. (2002) Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 33 347-354.